The FDA rejected ITM Isotope Technologies Munich’s radiopharmaceutical agent ITM-11 due to manufacturing issues, delivering a complete stop for a potential challenger to Novartis’ Lutathera in gastroenteropancreatic neuroendocrine tumors. The agency’s action delays the U.S. path for the product despite the company’s data package and prior indications of clinical performance. ITM said the FDA cited manufacturing problems rather than concerns about safety or efficacy, but the outcome still underscores how quality-system and third-party production dependencies can derail radiopharma timelines. For the competitive landscape, it preserves Lutathera’s near-term commercial position and removes a near-pivot alternative. In a field where supply chains and validated batch consistency are critical, the decision highlights the fragility of radiopharma development plans when manufacturing remediation is not fully resolved.